Severe community-acquired pneumonia in adults;Pneumonies communautaires graves de l'adulte

EMC - Anesthesie-Reanimation

Volumn 2, Issue 3, 2005, Pages 141-166

  Sollet, J P ^a   Legall, C ^a  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

"legionella pneumophila"; "streptococcus pneumoniae"; Acute respiratory failure; Community acquired pneumonia; Hypoxemia; Intensive care; Intracellular bacteria; Septic shock; Severe sepsis

Indexed keywords

EID: 32644446402     PISSN: 16386205     EISSN: 16386205     Source Type: Journal    
DOI: 10.1016/j.emcar.2005.08.002     Document Type: Short Survey

References (90)

1. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia: etiology, epidemiology, and prognostic factors. Chest 1994;105:1487-95.
2. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8.
3. Örtqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 1985;17:377-86.
4. The British Thoracic Society, the etiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992;86:7-13.
5. Leroy O, Santre C, Beuscart C, Georges H, Query B, Jacquier JM, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995;21:24-31.
6. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
7. Tuomanen El, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995;332:1280-4.
8. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:25-8.
9. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001;163:1599-604.
10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
11. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 1990;69:307-16.
12. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99.
13. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentlne leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753-9.
14. Guidet B, Maury E, Aegerter P. Scores de gravité. Lettre Infect 2001;16:154-62.
15. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
16. Fine MJ, Stone RA, Singer DE, Coley CM, Marrie TJ, Lave JR, et al. Processes and outcomes of care for patients with community-acquired pneumonia. Results from the Pneumonia patient Outcomes research team (PORT) cohort study. Arch Intern Med 1999;159:970-80.
17. Minogue MF, Coley CM, Fine MJ, Marrie TJ, Kapoor WN, Singer DE. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med 1998:31:376-80.
18. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the Management of Adults with Community-acquired Pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
19. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8.
20. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher MD, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33.
21. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
22. British Thoracic Society Standards of Care Committee. Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56(supplIV):1-64 (réactualisation 2004 sur www.brit-thoracic.org.uk) .
23. Leroy O, Devos P, Query B, Georges H, Vandenbussche C, Coffinier C, et al. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. Chest 1999;116:157-65.
24. Jehl F, Bédos JP, Poirier R, Léophonte P, Sirot J, Chardon H, et al. Enquête nationale sur les pneumonies communautaires à pneumocoque chez des malades adultes hospitalisés. Med Mal Infect 2002;32:267-83.
25. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4.
26. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44.
27. e conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française (SPILF). Med Mal Infect 2000;30:566-80.
28. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
29. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002;166:717-23.
30. Bartlett JG, Dowell SF, Mandell LA, File Jr. TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82.
31. Bartlett JG. Diagnosis of bacterial infection of the lung. Clin Chest Med 1987;8:119-34.
32. Östergaard L, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture or serology. Chest 1993;104:1400-7.
33. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia: etiology, prognosis, and treatment. Am Rev Respir Dis 1990;142:369-73.
34. Ruiz-Gonzalez A, Falguera M, Nogués A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999;106:385-90.
35. Torres A, El-Biary M. Invasive diagnostic techniques for pneumonia: protected specimen brush, bronchoalveolar lavage, and lung biopsy methods. Infect Dis Clin North Am 1998;12:701-22.
36. Örtqvist A, Kelin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990;97:576-82.
37. Jimenez P, Saldias F, Meneses M, Silva ME, Wilson MG, Otth L. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia. Comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest 1993;103:1023-7.
38. Antonelli M, Conti G, Rocco M, Arcangeli A, Cavalière F, Proietti R, et al. Noninvasive positive-pressure ventilation vs. conventional oxygen supplementation in hypoxemic patients undergoing diagnostic bronchoscopy. Chest 2002;121:1149-54.
39. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Infectious Diseases Society of America. Clin Infect Dis 1998;26:811-38.
40. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I. The value of routine microbial investigation In community-acquired pneumonia. Respir Med 1991;85:313-7.
41. Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995;152:1309-15.
42. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82.
43. Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004;169:342-7.
44. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003;123:1142-50.
45. Waterer GW, Jennings SG, Wunderink RG. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 1999;116:1278-81.
46. Gutierrez F, Masia M, Rodriguez JC, Ayelo A, Soldan B, Cebrian L, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003;36:286-92.
47. Levy M, Dromer F, Brion N, Leturdu F, Carbon F. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiologic investigations. Chest 1988;92:43-8.
48. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-58.
49. Glezen WP, Greenberg SB, Atmar RL, Pledra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000;283:499-505.
50. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med 2003;349:2431-41.
51. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, et al. Critically ill patients with severe acute respiratory syndrome. JAMA 2003;290:367-73.
52. Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management and prevention. Am J Med 1998;105:319-30.
53. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the ederly in nursing home. N Engl J Med 1985;312:1483-7.
54. Marrie TJ, Durant H, Kwan C. Nursing home-acquired pneumonia. A case-control study. J Am Geriatr Soc 1986;34:697-702.
55. Muder RR, Brennen C, Wagener M, Goetz A. Bacteremia in a long-term care facility: a five-year prospective study of 163 consecutive episodes. Clin Infect Dis 1992;14:647-54.
56. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31:383-421.
57. Fagon JY, Chastre J, Trouillet JL, Domart Y, Dombret MC, Bornet M, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: use of the protected specimen brush technique in 54 mechanically ventilated patients. Am J Respir Dis 1990;142:1004-8.
58. Torres A, Dorca J, Zalacain R, Bello S, El-Ebiary M, Molinos L, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease. A Spanish multicenter study. Am J Respir Crit Care Med 1996;154:1456-61.
59. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;333:845-51.
60. Centre National de Référence des Pneumocoques. Rapport d'activité 2003. Epidémiologie 2002. www.invs.sante.fr/ surveillance.
61. Laurens G, Murbach V, Cattier B, Chomarat M, Cottin J, Demachy MC, et al. Observatoires régionaux du pneumocoque: surveillance de la sensibilité aux antibiotiques des pneumocoques isolés en situation pathogène en France en 1999. Bull Epidémiol Hebd 2001;33:155-9.
62. Linares J, Alonso T, Perez JL, Ayats J, Dominguez MA, Pallares R, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother 1992;30:279-88.
63. Baquero F, Garcia-Rodriguez JA, Garcia de Loma J, Aguilar L. Antimicrobial resistance of 1 113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multi-center surveillance study. Antimicrob Agents Chemother 1999;43:357-9.
64. Vergnaud M, Bourdon S, Brun M, Cattier B, Chanal C, Chardon H, et al. Observatoires régionaux du pneumocoque : analyse de la résistance aux antibiotiques et des sérotypes de Streptococcus pneumoniae en 2001. Bull Epidémiol Hebd 2003;37:173-6.
65. Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
66. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
67. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-3.
68. Kupronis BA, Richards CL, Whitney CG. Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003;51:1520-5.
69. Nava JM, Bella F, Garau J, Lite J, Morera MA, Marti C, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis 1994;19:884-90.
70. Bèdos JP, Chevret S, Chastang C, Geslin P, Regnier B. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis 1996;22:63-72.
71. Einarsson S, Krustjansson M, Kristinsson KG, Kjartansson G, Jonsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis 1998;30:253-6.
72. Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835-42.
73. Winston LG, Perlman JL, Rose DA, Gerberding JL. Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis 1999;29:580-5.
74. Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003;9:590-9.
75. Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998;12:631-46.
76. Conte Jr. JE, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycine and erythromycin. Antimicrob Agents Chemother 1995;39:334-8.
77. Conte Jr. JE, Golden JA, Kipps J, Zurlinden E. Antimicrob Agents Chemother 2002;46:1475-80.
78. Huchon G, Woodhead M. European Study on Community-Acquired Pneumonia (ESOCAP) comittee. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998;11:986-91.
79. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumonias Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
80. Austrian R. Confronting drug-resistant pneumococci. Ann Intern Med 1994;121:807-9.
81. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999;107(1A):34S-43S.
82. Waterer GW, Somes GW, Wunderinck RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42.
83. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004;38:S328-40.
84. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001;429:209-29.
85. Pallares R, Viladrich PF, Linares J, Cabellos C, Gudiol F. Impact of antibiotic resistance on chemotherapy for pneumococcal infections. Microb Drug Resist 1998;4:339-47.
86. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, et al. Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Critical Care Medicine 2005;33:952-61.
87. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47.
88. Gauduchon V, Cozon G, Vandenesch F, Genestier AL, Eyssade N, Peyrol S, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004;189:346-53.
89. Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, et al. A randomized controlled trial of Fllgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 1998:178:1075-80.
90. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999;17:S91-3.